KREBSBIOKrebs Biochemicals and Industries Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on KREBSBIO — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Risk gate: safety score is only 25/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • ROCE: -19.1%
- • Dividend yield: 0.00%
- • MACD: bearish
- • Golden cross setup: SMA50 below SMA200
Bull case
- • Revenue growth: 27.4% YoY
- • Profit growth: 37.2% YoY
- • Promoter holding: 81.1%
- • RSI: 56
Bear case
- • ROCE: -19.1%
- • Dividend yield: 0.00%
- • MACD: bearish
- • Golden cross setup: SMA50 below SMA200
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROCE: -19.1%
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.79). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.